| __timestamp | CymaBay Therapeutics, Inc. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 35942000 |
| Thursday, January 1, 2015 | 8871000 | 40028000 |
| Friday, January 1, 2016 | 9645000 | 45853000 |
| Sunday, January 1, 2017 | 12387000 | 53816000 |
| Monday, January 1, 2018 | 14381000 | 60804000 |
| Tuesday, January 1, 2019 | 19238000 | 77252000 |
| Wednesday, January 1, 2020 | 17425000 | 45736000 |
| Friday, January 1, 2021 | 23040000 | 50323000 |
| Saturday, January 1, 2022 | 25116000 | 143526000 |
| Sunday, January 1, 2023 | 51953000 | 149182000 |
| Monday, January 1, 2024 | 154335000 |
Unlocking the unknown
In the competitive world of biotechnology, managing expenses is crucial for success. This chart highlights the Selling, General, and Administrative (SG&A) expense trends of Halozyme Therapeutics, Inc. and CymaBay Therapeutics, Inc. over the past decade. From 2014 to 2023, Halozyme consistently outspent CymaBay, with its SG&A expenses peaking at approximately $149 million in 2023, a staggering 315% increase from 2014. In contrast, CymaBay's expenses grew more modestly, reaching around $52 million in 2023, marking a 535% rise from its 2014 figures. This divergence in spending reflects differing strategic priorities and operational scales. While Halozyme's aggressive spending may indicate a robust expansion strategy, CymaBay's more conservative approach suggests a focus on sustainable growth. Understanding these trends provides valuable insights into each company's financial strategy and market positioning.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Who Optimizes SG&A Costs Better? Madrigal Pharmaceuticals, Inc. or CymaBay Therapeutics, Inc.
CymaBay Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? CymaBay Therapeutics, Inc. or Agios Pharmaceuticals, Inc.